氯喹与双氢青蒿素-哌喹联用高剂量伯氨喹7天或14天根治间日疟
在泰缅边境开展随机对照试验,680例无并发症间日疟患者随机接受氯喹或双氢青蒿素-哌喹联合伯氨喹(总剂量7mg/kg)7天或14天方案。1年复发率12%,7天与14天方案复发风险无差异(RR 1.15,95%CI 0.7-1.8)。除G6PD女性杂合子外,血液学毒性轻微;7天高剂量伯氨喹疗效与14天标准方案相似,但需床旁G6PD检测保障安全。
要点
- 7天高剂量伯氨喹(总剂量7mg/kg)根治间日疟疗效与14天标准方案相似。
- 氯喹与双氢青蒿素-哌喹均为血液期感染的高效治疗药物。
- G6PD女性杂合子使用高剂量伯氨喹需警惕溶血,建议床旁G6PD检测。
核心结论
- 7天高剂量伯氨喹方案的根治间日疟疗效与标准14天高剂量方案相似。
- 氯喹和双氢青蒿素-哌喹均为血液期感染的高效治疗药物。
- 应更广泛部署间日疟根治治疗,G6PD女性杂合子使用7天高剂量伯氨喹需床旁G6PD检测。
研究设计与样本
- 在泰国-缅甸边境开展随机对照试验,纳入680例无并发症间日疟患者。
- 随机接受氯喹(25mg base/kg)或双氢青蒿素-哌喹(双氢青蒿素7mg/kg和哌喹55mg/kg)联合伯氨喹。
- 伯氨喹为0.5 mg/kg/day连用14天或1 mg/kg/day连用7天(总剂量均为7mg/kg)。
- 比较42天内不良事件和1年复发率,并评估与第6天药物浓度的关系。
主要发现
- 共680例患者于2012年2月至2014年7月入组。
- 间日疟复发(均在35天后)发生于80/654(12%)患者,各治疗组间无差异。
- 与7天伯氨喹组相比,14天组复发的汇总相对风险为1.15(95%CI 0.7-1.8)。
- 除G6PD女性杂合子外,血细胞比容下降无临床意义;2例G6PD女性杂合子血细胞比容降至<23%需输血。
关键数值与推荐
- 伯氨喹总剂量7mg/kg,7天方案为1 mg/kg/day,14天方案为0.5 mg/kg/day。
- 氯喹剂量25mg base/kg;双氢青蒿素-哌喹剂量为双氢青蒿素7mg/kg和哌喹55mg/kg。
- 复发定义:1年内间日疟复发(所有复发均在35天后)。
- 14天组相比7天组复发相对风险1.15(95%CI 0.7-1.8)。
临床怎么用
- 7天高剂量伯氨喹可作为间日疟根治方案,疗效与14天方案相似。
- 氯喹和双氢青蒿素-哌喹均可用于间日疟血液期感染治疗。
- 使用7天高剂量伯氨喹前应进行定量床旁G6PD检测,尤其关注G6PD女性杂合子。
局限性
- 研究在泰缅边境单一地区进行,结果外推需谨慎。
- G6PD女性杂合子溶血风险需进一步量化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain. A randomized controlled trial was performed to compare the tolerability and radical curative efficacy of 7-day versus 14-day high-dose primaquine regimens (total dose 7mg/kg) with either chloroquine or dihydroartemisinin-piperaquine. METHODS: Patients with uncomplicated P. vivax malaria on the Thailand-Myanmar border were randomized to either chloroquine (25mg base/kg) or dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine, either 0.5 mg/kg/day for 14 days or 1 mg/kg/day for 7 days. Adverse events within 42 days and 1-year recurrence rates were compared and their relationship with day 6 drug concentrations assessed. RESULTS: Between February 2012 and July 2014, 680 patients were enrolled. P. vivax recurrences (all after day 35) occurred in 80/654 (12%) patients; there was no difference between treatments. Compared to the 7-day primaquine groups the pooled relative risk of recurrence in the 14-day groups was 1.15 (95% confidence interval 0.7 to 1.8). Hematocrit reductions were clinically insignificant except in G6PD female heterozygotes, 2 of whom had hematocrit reductions to <23% requiring blood transfusion. CONCLUSION: Radical cure should be deployed more widely. The radical curative efficacy in vivax malaria of 7-day high-dose primaquine is similar to the standard 14-day high-dose regimen. Chloroquine and dihydroartemisinin-piperaquine are both highly effective treatments of the blood stage infection. Quantitative point of care G6PD testing would ensure safe use of the 7-day high-dose primaquine regimen in G6PD heterozygous females. CLINICAL TRIALS REGISTRATION: NCT01640574.
引用
- Chu CS, Phyo AP, Turner C, et al. Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clin Infect Dis. 2019. PMID: 30952158. doi:10.1093/cid/ciy735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。